Inhibition of viral replication downregulates CD4 +CD25 high regulatory T cells and programmed death-ligand 1 in chronic hepatitis B

Viral Immunology

Volumn 25, Issue 1, 2012, Pages 21-28

  Nan, Xue Ping ^a   Zhang, Ye ^a   Yu, Hai Tao ^a   Sun, Rui Lin ^a   Peng, Mei Juan ^a   Li, Yu ^a   Su, Wen Jing ^a   Lian, Jian Qi ^a   Wang, Jiu Ping ^a   Bai, Xue Fan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 9; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TELBIVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; IMMUNOREGULATION; MALE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIGENS, CD274; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOWN-REGULATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-9; LYMPHOCYTE COUNT; MALE; NUCLEOSIDES; PYRIMIDINONES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84863011093     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0049     Document Type: Article

References (35)

1. Barboza L, Salmen S, Goncalves L, et al.: Antigen-induced regulatory T cells in HBV chronically infected patients. Virology 2007;368:41-49. (Pubitemid 47610682)
2. Bertoletti A, and Maini MK: Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 2000 3 387-392. (Pubitemid 30640363)
3. Boni C, Fisicaro P, Valdatta C, et al.: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225. (Pubitemid 46586915)
4. Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, and Wang GQ: Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2010;60:47-53.
5. Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, and Wang GQ: Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011;60:47-53.
6. Chen Z, Cheng Y, Xu Y, et al.: Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128:400-408.
7. Fisicaro P, Valdatta C, Massari M, et al.: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-693, 693 e1-e4.
8. Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, and Bertoletti A: Modulation of the CD8 + - T-cell response by CD4 + CD25 + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005;79: 3322-3328. (Pubitemid 40327921)
9. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, and Lok AS: Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075. (Pubitemid 46646501)
10. Hou J, Yin YK, Xu D, et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008;47: 447-454. (Pubitemid 351280712)
11. Kondo Y, Kobayashi K, Ueno Y, et al.: Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol 2006;12:4310-4317. (Pubitemid 44194522)
12. Lian JQ, Wang XQ, Zhang Y, Huang CX, and Bai XF: Correlation of circulating TLR2/4 expression with CD3+ /4 + /8 + T cells and Treg cells in HBV-related liver cirrhosis. Viral Immunol 2009;22:301-308.
13. Liaw YF, Gane E, Leung N, et al.: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
14. Lok AS, and McMahon BJ: Chronic hepatitis B. Hepatology 2001;34:1225-1241. (Pubitemid 33096596)
15. Lu FM, and Zhuang H: Management of hepatitis B in China. Chin Med J (Engl) 2009;122:3-4.
16. Maier H, Isogawa M, Freeman GJ, and Chisari FV: PD-1:PDL1 interactions contribute to the functional suppression of virus-specific CD8 + T lymphocytes in the liver. J Immunol 2007;178:2714-2720. (Pubitemid 46333147)
17. Miyara M, and Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. TrendsMolMed 2007;13:108-116. (Pubitemid 46341958)
18. Nan XP, Zhang Y, Yu HT, Li Y, Sun RL, Wang JP, and Bai XF: Circulating CD4 + CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol 2010;23: 63-70.
19. Nowak EC, Weaver CT, Turner H, et al.: IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009;206: 1653-1660.
20. Peng G, Li S, Wu W, Sun Z, Chen Y, and Chen Z: Circulating CD4 + CD25 + regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008;123:57-65. (Pubitemid 350255997)
21. Peng G, Li S, Wu W, Tan X, Chen Y, and Chen Z: PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008;45:963-970. (Pubitemid 350019503)
22. Ribeiro RM, Germanidis G, Powers KA,. Pellegrin B, Nikolaidis P, Perelson AS, and Pawlotsky JM: Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 2010;202:1309-1318.
23. Speletas M, Argentou N, Germanidis G, et al.: Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 2011;827:565.
24. Sprengers D, Stoop JN, Binda RS, et al.: Induction of regulatory T-cells and interleukin-10-producing cells in nonresponders to pegylated interferon-alpha therapy for chronic hepatitis B. Antiviral Ther 2007;12:1087-1096. (Pubitemid 350114989)
25. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, and Janssen HL: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778. (Pubitemid 40462939)
26. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, and Janssen HL: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007;361:141-148. (Pubitemid 46551232)
27. Temann UA, Laouar Y, Eynon EE, Homer R, and Flavell RA: IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. Int Immunol 2007;19:1-10. (Pubitemid 46017882)
28. Visvanathan K, Skinner NA, Thompson AJ, et al.: Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-110. (Pubitemid 46150869)
29. Wang Y, and Jia J: Control of hepatitis B in China: prevention and treatment. Expert Rev Anti Infect Ther 2011;9: 21-25.
30. Xie Z, Chen Y, Zhao S, et al.: Intrahepatic PD-1/PD-L1 upregulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 2009;38:624-638.
31. Xu D, Fu J, Jin L, et al.: Circulating and liver resident CD4+ CD25 + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739-747. (Pubitemid 43939189)
32. Yang G, Liu A, Xie Q, Guo TB, Wan B, Zhou B, and Zhang JZ: Association of CD4 + CD25 + Foxp3 + regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007;19:133-140. (Pubitemid 46179008)
33. Zeng Z, Shi F, Zhou L, et al.: Upregulation of circulating PDL1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One 2011;6:e23621.
34. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, and Wang FS: Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2011;5:e13869.
35. Zhang Y, Lian JQ, Huang CX, et al.: Overexpression of tolllike receptor 2/4 on monocytes modulates the activities of CD4( + )CD25( + ) regulatory T cells in chronic hepatitis B virus infection. Virology 2010;397:34-42.